Publication Name	World Journal of Gastroenterology
Manuscript ID	6262
Country	South Korea

Received	2013-10-11 16:13
Peer-Review Started	2013-10-12 14:05
To Make the First Decision	2014-01-15 12:23
Return for Revision	2014-01-20 12:37
Revised	2014-02-24 17:19
Second Decision	2014-04-03 10:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-03 12:30
Articles in Press	2014-05-23 10:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-06 16:35
Publish the Manuscript Online	2014-06-21 13:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Evidence-Based Medicine
Article Title	Inhibitory effects of rapamycin on the different stages of hepatic fibrosis
Manuscript Source	Invited Manuscript
All Author List	Yun Jeung Kim, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Seung Moo Noh, Dae Young Kang and Byung Seok Lee
Funding Agency and Grant Number	Funding Agency Grant Number YUHAN Cooperation
Corresponding Author	Byung Seok Lee, Associate Professor, Department of Internal Medicine, Chungnam National University School of Medicine, 640 Daesa-Dong, Jung-Gu, Daejeon 301-721, South Korea. gie001@cnuh.co.kr
Key Words	Liver cirrhosis; Sirolimus; Transforming growth factor beta; Platelet-derived growth factor; Ribosomal protein S6 kinases
Core Tip	Liver cirrhosis is a serious disease causing significant mortality, but a curative treatment has not yet been developed. Therefore, there is great interest within the field of drug development in developing agents capable of inhibiting the progression of hepatic fibrosis. Rapamycin is an immunosuppressive agent that is also expected to attenuate the progression of liver fibrosis. We therefore aimed to investigate the inhibitory effects of rapamycin in the early and late stages of fibrosis, with the goal of contributing to the development of novel fibrosis treatments.
Publish Date	2014-06-21 13:56
Citation	Kim YJ, Lee ES, Kim SH, Lee HY, Noh SM, Kang DY, Lee BS. Inhibitory effects of rapamycin on the different stages of hepatic fibrosis. World J Gastroenterol 2014; 20(23): 7452-7460
URL	http://www.wjgnet.com/1007-9327/full/v20/i23/7452.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i23.7452

Full Article (PDF)	WJG-20-7452.pdf
Full Article (Word)	WJG-20-7452.doc
Manuscript File	6262-Review.docx
Answering Reviewers	6262-Answering reviewers.pdf
Copyright License Agreement	6262-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6262-Language certificate.pdf
Peer-review Report	6262-Peer reviews.pdf
Scientific Editor Work List	6262-Scientific editor work list.doc